The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The development and validation of a CT-based radiomics signature for the preoperative discrimination of stage I-II and stage III-IV colorectal cancer
Open accessAbstract
// Cuishan Liang 1, 2, * , Yanqi Huang 1, 2, * , Lan He 1, 3 , Xin Chen 4 , Zelan Ma 1, 2 , Di Dong 5 , Jie Tian 5 , Changhong Liang 1 , Zaiyi Liu 1 1 Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China 2 Graduate College, Southern Medical University, Guangzhou, 510515, China 3 School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China 4 Department of Radiology, The Affiliated Guangzhou First People’ Hospital, Guangzhou Medical University, Guangzhou, 510180, China 5 Key Laboratory of Molecular Imaging, Chinese Academy of Sciences, Beijing, 100190, China * These authors have contributed equally to this work Correspondence to: Zaiyi Liu, email: zyliu@163.com Changhong Liang, email: cjr.lchh@vip.163.com Keywords: colorectal cancer, computed tomography, radiomics signature, predictor, stage Received: December 25, 2015 Accepted: April 2, 2016 Published: April 22, 2016 ABSTRACT Objectives: To investigative the predictive ability of radiomics signature for preoperative staging (I-II vs. III-IV) of primary colorectal cancer (CRC). Methods: This study consisted of 494 consecutive patients (training dataset: n=286; validation cohort, n=208) with stage I–IV CRC. A radiomics signature was generated using LASSO logistic regression model. Association between radiomics signature and CRC staging was explored. The classification performance of the radiomics signature was explored with respect to the receiver operating characteristics(ROC) curve. Results: The 16-feature-based radiomics signature was an independent predictor for staging of CRC, which could successfully categorize CRC into stage I-II and III-IV ( p <0.0001) in training and validation dataset. The median of radiomics signature of stage III-IV was higher than stage I-II in the training and validation dataset. As for the classification performance of the radiomics signature in CRC staging, the AUC was 0.792(95%CI:0.741-0.853) with sensitivity of 0.629 and specificity of 0.874. The signature in the validation dataset obtained an AUC of 0.708(95%CI:0.698-0.718) with sensitivity of 0.611 and specificity of 0.680. Conclusions: A radiomics signature was developed and validated to be a significant predictor for discrimination of stage I-II from III-IV CRC, which may serve as a complementary tool for the preoperative tumor staging in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132
Radiomics: the process and the challenges
Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., Forster, K., Aerts, H. J. W. L., Dekker, A., Fenstermacher, D., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.010 · Cited by 2,258 · cited 1×
“Radiomics, which enables a high-throughput extraction of quantitative features from medical images, has facilitated the construction of powerful signatures [18, 19].”
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma
Coroller, T. P., Grossmann, P., Hou, Y., Rios Velazquez, E., Leijenaar, R. T. H., Hermann, G., Lambin, P., Haibe-Kains, B., Mak, R. H., & Aerts, H. J. W. L. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.015 · Cited by 695 · cited 1×
“…has been demonstrated to be a significant predictor for the survival in oropharyngeal squamous cell carcinoma (p = 0.004), a prognostic biomarker for distant metastasis for lung adenocarcinoma patients (AUC = 0.61), and a classifier associated with the staging in lung, head and neck cancer [24–26].”
Influential
Cited by
Radiomics: the bridge between medical imaging and personalized medicine
Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.141 · Cited by 5,688
Limkin, E. J., Sun, R., Dercle, L., Zacharaki, E. I., Robert, C., Reuzé, S., Schernberg, A., Paragios, N., Deutsch, E., & Ferté, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx034 · Cited by 757
Beyond imaging: The promise of radiomics
Avanzo, M., Stancanello, J., & El Naqa, I. (2017) · Physica Medica · doi:10.1016/j.ejmp.2017.05.071 · Cited by 483
Larue, R. T. H. M., Defraene, G., De Ruysscher, D., Lambin, P., & van Elmpt, W. (2017) · The British Journal of Radiology · doi:10.1259/bjr.20160665 · Cited by 363
Feng, B., Chen, X., Chen, Y., Li, Z., Hao, Y., Zhang, C., Li, R., Liao, Y., Zhang, X., Huang, Y., et al. (2019) · Clinical Radiology · doi:10.1016/j.crad.2019.03.018 · Cited by 28
Self-citation
Metadata
- Authors
- Liang, C., Huang, Y., He, L., Chen, X., Ma, Z., Dong, D., Tian, J., Liang, C., & Liu, Z.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-22
- Volume
- 7
- Issue
- 21
- Pages
- 31401-31412
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2336302003
- Cited by
- 169
- References
- 6
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The development and validation of a CT-based radiomics signature for the preoperative discrimination of stage I-II and stage III-IV colorectal cancer. https://app.cochat.ai/papers/10.18632/oncotarget.8919
- The paper
- Liang, C., Huang, Y., He, L., Chen, X., Ma, Z., Dong, D., Tian, J., Liang, C., & Liu, Z. (2016). The development and validation of a CT-based radiomics signature for the preoperative discrimination of stage I-II and stage III-IV colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.8919
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.